<DOC>
	<DOCNO>NCT01448044</DOCNO>
	<brief_summary>The purpose study compare sustain virologic response post treatment Week 12 cohort ( BMS-790052/Pegylated-interferon alfa 2a ( pegIFNα-2a ) /Ribavirin ( RBV ) versus placebo/PegIFNα-2a/RBV ) .</brief_summary>
	<brief_title>Phase III BMS-790052 Add-On Peg-Interferon Alfa-2a Ribavirin Naive Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants chronically infect HCV Genotype 4 HCV RNA viral load ≥ 10,000 IU/mL No previous exposure interferon formulation , RBV HCV direct antiviral agent Results liver biopsy obtain within three year prior enrollment demonstrate absence cirrhosis . Participants compensate cirrhosis permit , however , prior biopsy permit Evidence decompensated liver disease Documented suspect Hepatocellular carcinoma ( HCC ) Positive Hepatitis B surface antigen ( HBsAg ) Human immunodeficiency virus1 ( HIV1 ) /HIV2 antibody screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hepatitis C virus</keyword>
</DOC>